Liraglutide Subcutaneous Injection Suppliers & Bulk Manufacturers
Available Forms: Subcutaneous injection/Pre filled Pen
Available Strengths: 6 mg/mL solution
Reference Brands: Victoza(US & EU)
Category:
Diabetes
Liraglutide is a GLP-1 receptor agonist that mimics incretin hormones, stimulating insulin secretion, suppressing glucagon release, and delaying gastric emptying. Benefits include improved glycemic control in type 2 diabetes and weight loss (obesity management). It also reduces cardiovascular risk in high-risk patients. Administered once daily for convenience.
Liraglutide subcutaneous injection is available in Subcutaneous injection/Pre filled Pen
and strengths such as 6 mg/mL solution.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Liraglutide subcutaneous injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Liraglutide subcutaneous injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Liraglutide injection, approved by both the FDA and EMA, is prescribed for type 2 diabetes, weight management, and cardiovascular risk reduction. Marketed under brand names like Victoza® and Saxenda®, it requires a prescription and proper medical supervision. In the U.S., it carries a boxed warning for thyroid C-cell tumors, while the EU mandates PSURs and risk management plans. Cold-chain storage and pharmacovigilance are required in both regions. For regulatory-compliant sourcing and global distribution of liraglutide injection, visit PharmaTradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing